BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Archives for Cade Hildreth (CEO)

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®

May 16, 2022 By Cade Hildreth (CEO) 1 Comment

PolarityTE RMAT

SALT LAKE CITY, May 13, 2022 –PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the Company’s open IND. [Read more…]

Filed Under: Cell Therapy, Press Releases

What Is An RMAT? List of Publicly Announced RMAT Designations (64)

May 15, 2022 By Cade Hildreth (CEO) 4 Comments

Advanced Therapy | What is a RMAT Designation (and Who Has One)?

To date, 64 RMAT (Regenerative Medicine Advanced Therapy) designations have been publicly announced. However, the FDA states it has received 187 requests and issued 70, which means that a handful are not yet public knowledge.

Sponsors of cell and gene therapies are eligible to obtain an RMAT designation from the U.S. FDA if their product is intended to treat serious or life-threatening diseases and there is preliminary clinical evidence that it can address unmet medical needs.

Thus far, AlloVir is the only company to receive three RMATs, while 5 companies (Abeona Therapeutics, Athersys, CARsgen Therapeutics, Rocket Pharmaceuticals, and CRISPR Therapeutics) have received two RMAT designations from the U.S. FDA.

[Read more…]

Filed Under: Cell Therapy, Stem Cell News Tagged With: RMAT

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

May 12, 2022 By Cade Hildreth (CEO) Leave a Comment

i-peaces-cell-manufacturing

PALO ALTO, Calif., May 11, 2022 – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up in the field of GMP cell manufacturing CDMO, announced that the company, in collaboration with Genequest Inc., a Tokyo-based direct-to-consumer genetic testing service provider, established a data-driven method to identify potential cell donors with specific haplotypes. With this high-throughput method, the company has already succeeded in identifying 1,547 HLA-homozygous potential donors and has already generated iPSCs. [Read more…]

Filed Under: Cord Blood

Stem Cell Treatments For COPD in 2022

May 12, 2022 By Cade Hildreth (CEO) Leave a Comment

Stem Cell Treatments For COPD

A diagnosis of chronic obstructive pulmonary disease (COPD) can be alarming, but thanks to stem cell treatments for COPD, the situation may not be dire. Once a patient develops COPD, it means that he or she has developed complications to existing breathing problems. The chronic disease happens when inflammation in the lung interferes with airflow.

Not being able to breathe properly and having frequent chest tightness can be distressing, especially when it is caused by a chronic disease, rather than a temporary illness like bronchitis. Thankfully, new options for treatment emerge every day. Among these options are stem cell treatments for COPD. [Read more…]

Filed Under: Cell Therapy, Stem Cells

Global Cord Blood Corporation Announces Entry into Cell Therapy Market by Acquiring Cellenkos and Its Products Rights

May 8, 2022 By Cade Hildreth (CEO) Leave a Comment

GCBC Cellenkos

HONG KONG, April 29, 2022 — Global Cord Blood Corporation (NYSE: CO, “GCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, announced today that the Company will acquire 100% of Cellenkos, Inc (“CLNK”) and the rights to develop and commercialize all of its existing and future products worldwide except those related to CLNK’s existing collaboration with Incyte Corporation (Nasdaq: INCY, “Incyte”). [Read more…]

Filed Under: Cell Therapy, Cord Blood

  • 1
  • 2
  • 3
  • …
  • 265
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.